RETRACTED: Identification of miR-758-3p as Potential Modulator of CBX5 Expression in Gastric Cancer

Guo, Jin-Xing; Zhang, Zichao; Pan, Longfa; Zhou, Yiming

doi:10.1177/1533033818816061

Cited by 26 publications

(25 citation statements)

References 22 publications

(39 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results imply that miR-758 serves as a tumor suppressor in CRC progression. Previous studies have also reported the downregulation of miR-758 in human cancers, such as ovarian and gastric cancer (17,18). Also, miR-758 has been found to inhibit cell migration, invasion and proliferation in bladder cancer, hepatocellular carcinoma and glioblastoma (19)(20)(21).…”

Section: Discussionmentioning

confidence: 92%

MicroRNA‑758 acts as a tumor inhibitor in colorectal cancer through targeting PAX6 and regulating PI3K/AKT pathway

Zhang¹,

Zhang

et al. 2020

Oncol Lett

View full text Add to dashboard Cite

Recently, a number of microRNAs (miRNAs) have been reported to play different roles in human cancers, including colorectal cancer (CRC). However, the specific role of miR-758 has not been clarified in CRC. Therefore, the aim of the present study was to explore the role of miR-758 in CRC. RT-qPCR and western blot analysis were used to quantify the expression of miR-758 and genes. The function of miR-758 in CRC was investigated using Transwell, CCK-8 and luciferase reporter assays. According to the results, the downregulation of miR-758 expression was associated with aggressive behavior and poor prognosis in CRC patients. miR-758 was shown to restrain the cell viability and metastasis in CRC. In addition, it was confirmed that miR-758 directly targets PAX6 and inhibits CRC progression through targeting PAX6. The results also revealed that miR-758 blocked EMT and PI3K/AKT pathway in CRC. In conclusion, miR-758 acts as a tumor suppressor in CRC by downregulating PAX6.

show abstract

Section: Discussionmentioning

confidence: 92%

MicroRNA‑758 acts as a tumor inhibitor in colorectal cancer through targeting PAX6 and regulating PI3K/AKT pathway

Zhang¹,

Zhang

et al. 2020

Oncol Lett

View full text Add to dashboard Cite

show abstract

“…16 Meanwhile, Guo and colleagues have reported that miR-758-3p can serve as a tumor suppressor, playing a crucial inhibitory role in the proliferation, migration and invasion of gastric cancer via chromobox 5. 17 Moreover, miR-758-3p has also been shown to act as a tumor suppressor in the initiation of papillary thyroid cancer via inhibition of cell proliferation and invasion, and promotion of cell apoptosis. 18 Overall, for the first time, this study determined the prognostic and tumor suppressor role of miR-758-3p in the progression of ccRCC.…”

Section: Discussionmentioning

confidence: 99%

“…[11][12][13] Recently, increasing evidence has indicated that miRNAs can act as oncogenes or tumor suppressors in the regulation of ccRCC development and progression. 14 It has been widely reported in recent years, that miR-758-3p plays critical roles in different cancer types, including hepatocellular carcinoma, 15 bladder cancer, 16 gastric cancer, 17 and papillary thyroid cancer. 18 Nevertheless, the roles of miR-758-3p in ccRCC remain unclear.…”

Section: Introductionmentioning

confidence: 99%

<p>miR-758-3p Inhibits Proliferation, Migration, and Invasion of Clear Cell Renal Cell Carcinoma and Predicts Favorable Prognosis</p>

Liu

2020

CMAR

View full text Add to dashboard Cite

Background: Although miR-758-3p has been reported to be associated with multiple cancers, including hepatocellular carcinoma, bladder cancer, gastric cancer and papillary thyroid cancer, its role in clear cell renal cell carcinoma (ccRCC) remains unclear. Methods: The expression levels of miR-758-3p in ccRCC tissues and cell lines were examined using qRT-PCR. Survival analysis was performed using Kaplan-Meier, while the prognostic significance of miR-758-3p was evaluated by Cox regression analysis. The effects of miR-758-3p on cell proliferation, migration and invasion were analyzed with CCK-8, crystal violet and transwell assays. Luciferase reporter assays were performed to determine the effect of miR-758-3p on MDM2. Western blot was applied to measure the expression of MDM2. Results: The expression levels of miR-758-3p were down-regulated in human ccRCC tissues and cell lines. Moreover, the expression of miR-758-3p was closely associated with histological grade, TNM stage and vascular invasion. High expression of miR-758-3p was found to be capable of predicting favorable clinical prognosis in ccRCC patients. Additionally, whilst the proliferation, migration and invasion of ccRCC cells were inhibited upon overexpression of miR-758-3p, the effects were reversed upon miR-758-3p knockdown. Moreover, miR-758-3p was a modulator of MDM2 in ccRCC. Conclusion: This study demonstrated that miR-758-3p is a potential prognostic biomarker for ccRCC patients. Data from this study showed that miR-758-3p exhibits different biological functions that inhibit the progression of ccRCC cells, hence it can be a potential therapeutic target candidate for treating ccRCC.

show abstract

“…The 17 TFs, except FOXK2, LHX2, SPDEF, TRIM38, ZHX3, and ZXDB, were reported to be involved in the malignant phenotype of OC. The CBX5, a member of chromobox (CBX) family, was suggested to function as a prognostic biomarker and potential target for various cancers; including gastric cancer, breast cancer, and lung cancer [37][38][39][40]. The expression of CBX5 was elevated in gastric cancer tumor tissues and it promoted cell proliferation, migration, and invasion [38].…”

Section: Discussionmentioning

confidence: 99%

“…The CBX5, a member of chromobox (CBX) family, was suggested to function as a prognostic biomarker and potential target for various cancers; including gastric cancer, breast cancer, and lung cancer [37][38][39][40]. The expression of CBX5 was elevated in gastric cancer tumor tissues and it promoted cell proliferation, migration, and invasion [38]. It was highly expressed in breast cancer tissues and correlated to relapse-free survival (RFS) for the patients [39].…”

Section: Discussionmentioning

confidence: 99%

Development of a novel transcription factors-related prognostic signature for serous ovarian cancer

Liu

et al. 2020

Preprint

View full text Add to dashboard Cite

BackgroundOvarian cancer (OC) is one of the most lethal gynecological cancer globally. Serous ovarian cancer (SOC) is most common pathological type of ovarian cancer. Growing evidence suggests that transcription factors (TFs) play vital roles in serous ovarian cancer (SOC). In the present study, we aimed to develop a transcription factors-related prognostic signature to better predict the survival in patients with SOC.Materials and methodsThe TFs mRNA expression profiles of 564 SOC subjects in the TCGA database, and 70 SOC subjects in the GEO database were screened. Lasso cox regression and consensus clustering analysis were utilized to construct a novel TFs related signature and cluster model, respectively. Genomic alternative analysis was used to elaborate on the association between the TFs related prognostic signature and genomic aberrations. GSEA analysis was applied to identify the biological functional difference between high risk-score group and low-risk score group.ResultsA 17-TFs related prognostic signature was constructed using lasso cox regression and validated in the TCGA and GEO cohorts. Consensus clustering analysis was applied to establish a cluster model. The 17-TFs related prognostic signature, risk score, and cluster models were effective at accurately distinguishing the prognosis of SOC. The GSEA assay results suggested that there was a significant difference in the inflammatory and immune response pathways between the high-risk and low-risk score groups. Immune infiltration, immunotherapy, and chemotherapy responses were analyzed due to the significant difference in the regulation of lymphocyte migration and T cell-mediated cytotoxicity between the two groups; indicating that patients with low-risk score were more likely to respond anti-PD-1, etoposide, paclitaxel, and veliparib but not to gemcitabine, doxorubicin, docetaxel, and cisplatin. Also, the prognostic nomogram model revealed that the risk score was a good prognostic indicator for SOC patients.ConclusionsIn conclusion, we explored the prognostic values of TFs in SOC and developed a 17-TFs related prognostic signature to predict the survival of SOC patients.

show abstract

RETRACTED: Identification of miR-758-3p as Potential Modulator of CBX5 Expression in Gastric Cancer

Cited by 26 publications

References 22 publications

MicroRNA‑758 acts as a tumor inhibitor in colorectal cancer through targeting PAX6 and regulating PI3K/AKT pathway

MicroRNA‑758 acts as a tumor inhibitor in colorectal cancer through targeting PAX6 and regulating PI3K/AKT pathway

<p>miR-758-3p Inhibits Proliferation, Migration, and Invasion of Clear Cell Renal Cell Carcinoma and Predicts Favorable Prognosis</p>

Development of a novel transcription factors-related prognostic signature for serous ovarian cancer

Contact Info

Product

Resources

About